Comprehensive evaluation of patients with primary hyperoxaluria type 1: A nationwide study

Sevcan A. Bakkaloğlu,Bahar Büyükkaragöz,Ayşe Seda Pınarbaşı,Emre Leventoğlu,Seha Saygılı,Elif Çomak,Zeynep Y. Yıldırım,Nurver Akıncı,İsmail Dursun,Aysun Karabay Bayazıt,Aslı Kavaz Tufan,Sema Akman,Alev Yılmaz,Aytül Noyan,Ayşe Ağbaş,Erkin Serdaroğlu,Ali Delibaş,Ahmet Midhat Elmacı,Mehmet Taşdemir,Fatih S. Ezgü,Lale Sever
DOI: https://doi.org/10.1111/nep.14273
2024-02-01
Nephrology
Abstract:Summary at a glance PH1 is not an isolated kidney disease but a systemic disease that can affect almost all systems. The fact that kidney damage develops earlier and is the leading problem compared with other manifestations should not cause the extrarenal manifestations of PH1 to be ignored. Background Primary hyperoxaluria type 1 (PH1) is characterized by increased endogenous oxalate production and deposition as calcium oxalate crystals. The main manifestations are nephrocalcinosis/nephrolithiasis, causing impaired kidney function. We aimed to evaluate the clinical characteristics and overall outcomes of paediatric PH1 patients in Turkey. Methods This is a nationwide, multicentre, retrospective study evaluating all available paediatric PH1 patients from 15 different paediatric nephrology centres in Turkey. Detailed patient data was collected which included demographic, clinical and laboratory features. Patients were classified according to their age and characteristics at presentation: patients presenting in the first year of life with nephrocalcinosis/nephrolithiasis (infantile oxalosis, Group 1), cases with recurrent nephrolithiasis diagnosed during childhood (childhood‐onset PH1, Group 2), and asymptomatic children diagnosed with family screening (Group 3). Results Forty‐eight patients had a mutation consistent with PH1. The most common mutation was c.971_972delTG (25%). Infantile oxalosis patients had more advanced chronic kidney disease (CKD) or kidney failure necessitating dialysis (76.9% vs. 45.5%). These patients had much worse clinical course and mortality rates seemed to be higher (23.1% vs. 13.6%). Patients with fatal outcomes were the ones with significant comorbidities, especially with cardiovascular involvement. Patients in Group 3 were followed with better outcomes, with no kidney failure or mortality. Conclusion PH1 is not an isolated kidney disease but a systemic disease. Family screening helps to preserve kidney function and prevent systemic complications. Despite all efforts made with traditional treatment methods including transplantation, our results show devastating outcomes or mortality.
urology & nephrology
What problem does this paper attempt to address?